References
- Kim N, He N, Kim C, et al. Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer. 2012;131:2456–2464.
- Goyanes A, Buanz AB, Hatton GB, et al. 3D printing of modified-release aminosalicylate (4-ASA and 5-ASA) tablets. Eur J Pharm Biopharm. 2015a;89:157–162.
- Dragone V, Sans V, Rosnes MH, et al. 3D-printed devices for continuous-flow organic chemistry. Beilstein J Org Chem. 2013;9:951.
- Khaled SA, Burley JC, Alexander MR, et al. 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. J Control Release. 2015;217:308–314.
- Kitson PJ, Rosnes MH, Sans V, et al. Configurable 3D-Printed millifluidic and microfluidic ‘lab on a chip’ reactionware devices. Lab Chip. 2012;12:3267–3271.
- Kitson PJ, Symes MD, Dragone V, et al. Combining 3D printing and liquid handling to produce user-friendly reactionware for chemical synthesis and purification. Chem Sci. 2013;4:3099–3103.
- Skowyra J, Pietrzak K, Alhnan MA. Fabrication of extended-release patient-tailored prednisolone tablets via fused deposition modelling (FDM) 3D printing. Eur J Pharm Sci. 2015;68:11–17.
- Yu DG, Branford-White C, Ma ZH, et al. Novel drug delivery devices for providing linear release profiles fabricated by 3DP. Int J Pharm. 2009a;370:160–166.
- Katstra WE, Palazzolo RD, Rowe CW, et al. Oral dosage forms fabricated by three dimensional printing. J Control Release. 2000;66:1–9.
- Yu DG, Yang XL, Huang WD, et al. Tablets with material gradients fabricated by three-dimensional printing. J Pharm Sci. 2007;96:2446–2456.
- Yu DG, Shen XX, Branford-White C, et al. Novel oral fast-disintegrating drug delivery devices with predefined inner structure fabricated by three-dimensional printing. J Pharm Pharmacol 2009b;61:323–329.
- Goyanes A, Robles Martinez P, Buanz A, et al. Effect of geometry on drug release from 3D printed tablets. Int J Pharm. 2015b;494:657–663.
- Khaled SA, Burley JC, Alexander MR, et al. Desktop 3D printing of controlled release pharmaceutical bilayer tablets. Int J Pharm. 2014;461:105–111.
- Huang W, Zheng Q, Sun W, et al. Levofloxacin implants with predefined microstructure fabricated by three-dimensional printing technique. Int J Pharm. 2007;339:33–38.
- Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119:8S–21S.
- Johnson JA, Gong L, Whirl‐Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90:625–629.
- Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin‐Nature or nurture. Clin Pharmacol Ther. 2001;70:159–164.
- Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–2012.
- Chinese Pharmacopoeia Committee. Pharmacopoeia of the People’s Republic of China, vol. II and IV. Beijing: Chemical Industry Press; 2015
- Fell JT, Newton JM. Determination of tablet strength by the diametral-compression test. J Pharm Sci. 1970;59:688–691.
- Douroumis DD, Gryczke A, Schminke S. Development and evaluation of cetirizine HCl taste-masked oral disintegrating tablets. AAPS PharmSciTech. 2011;12:141–151.
- Gohel MC, Parikh RK, Brahmbhatt BK, et al. Preparation and assessment of novel coprocessed superdisintegrant consisting of crospovidone and sodium starch glycolate: a technical note. AAPS PharmSciTech. 2007;8:E63–E69.